Cultural and creative ecosystems in medium-sized cities: Evolution in times of economic crisis and pandemic

This article seeks to forecast the short-and medium-term impacts of the coronavirus pandemic on the cultural and creative ecosystems of the 81 cities in Spain with between 50, 000 and 100, 000 inhabitants. Data on employment in nine sectors (per NACE Rev. 2) support the characterization of cultural ecosystems based on their dynamism, specialization, and propensity to form clusters (thanks to the co-location of certain sectors, meant to generate inter-sectoral spillovers and cross-sector synergies). The applied methodology consists of comparing these three attributes during and following the 2008 financial crisis. Then, any changes observed are interpreted in light of arguments from the COVID-19 literature, and from our own analysis, in order to assess the probability of recurrence (or nonrecurrence) during the current pandemic. Throughout this process, the metropolitan or non-metropolitan position of cities is taken into consideration. A first conclusion is that, as in the financial crisis, the behavior of ecosystems during the pandemic will be asymmetric. Secondly, metropolitan and non-metropolitan cities will maintain their distinctive sectoral specializations. Non-metropolitan cities appear to be more vulnerable for their strong connection to creative sectors most affected by the pandemic, although some can take advantage of good cultural supply and proximity to metropolitan centers. Metropolitan cities seem more secure, thanks to the higher presence of less vulnerable sectors (due to elevated and accelerating digitization). Nevertheless, most functional clusters were diminished during the financial crisis, and it seems unlikely that sectoral co-locations will re-emerge in a post-pandemic scenario as a business strategy, at least in the short term. Beyond these forecasts, we recommend dealing with certain structural failures of these ecosystems, especially the vulnerability and precariousness of most cultural and creative companies and workers

New insights into the genetic etiology of Alzheimer's disease and related dementias

Characterization of the genetic landscape of Alzheimer's disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/'proxy' AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele

Localising and globalising the depopulation dividend: theory and evidence from three countries in three world regions

We bring together evidence from three countries in differing world regions to ask whether or how depopulation is delivering socio-environmental gains – what we call a ‘depopulation dividend’. We first discuss the depopulation problem itself and introduce the idea of a ‘depopulation dividend’, and we present research on national and sub-national depopulation processes in each country, beginning with demographic and environmental change in Japan. Following that we introduce socio-economic outcomes in Spain and New Zealand. Overall, we present a positive perspective on depopulation – an issue that is usually presented in the negative – and we localize and globalize Japan’s, Spain’s, and New Zealand’s experiences therein

Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19

Altres ajuts: Fondo Europeo de Desarrollo Regional (FEDER); Sociedad Española de Trasplante.Introduction: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients. Methods: We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed. Results: Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged ≥65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug. Conclusion: In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy

Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

Genetic discoveries of Alzheimer’s disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer’s disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer’s disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer’s disease

Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

Genetic discoveries of Alzheimer’s disease are the drivers of our understanding, and together with polygenetic risk stratification can contribute towards planning of feasible and efficient preventive and curative clinical trials. We first perform a large genetic association study by merging all available case-control datasets and by-proxy study results (discovery n = 409,435 and validation size n = 58,190). Here, we add six variants associated with Alzheimer’s disease risk (near APP, CHRNE, PRKD3/NDUFAF7, PLCG2 and two exonic variants in the SHARPIN gene). Assessment of the polygenic risk score and stratifying by APOE reveal a 4 to 5.5 years difference in median age at onset of Alzheimer’s disease patients in APOE ɛ4 carriers. Because of this study, the underlying mechanisms of APP can be studied to refine the amyloid cascade and the polygenic risk score provides a tool to select individuals at high risk of Alzheimer’s disease. © 2021, The Author(s)